Physician profile
Marwa Hakimi
NPI 1134522584
$4,356.86
in general payments reported to CMS, 2019-2025
19 companies · $2,129 in 2025
The $2,129 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,228 · 2025: $2,129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,987 · Education: $307 · Travel and Lodging: $62.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,987.28 |
| Education | $307.08 |
| Travel and Lodging | $62.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $796.78 | 2024-2025 | |
| Lilly USA, LLC | $722.25 | 2024-2025 | Taltz, Ebglyss, Olumiant |
| Janssen Biotech, INC. | $682.52 | 2024-2025 | Tremfya, Stelara, Simponi Aria |
| Genzyme Corporation | $458.33 | 2024-2025 | |
| Incyte Corporation | $285.34 | 2024-2025 | Opzelura |
| Ucb, INC. | $251.90 | 2024-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $243.96 | 2024-2025 | Dupixent |
| Galderma Laboratories, L.P. | $222.29 | 2024-2025 | Nemluvio, Dysport |
| Pfizer INC. | $216.48 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.59 | 2024 | |
| Dermavant Sciences, INC. | $91.38 | 2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $70.90 | 2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $53.43 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $27.16 | 2024 | Sotyktu |
| Biofrontera INC. | $25.24 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $25.07 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $22.17 | 2024 | Jublia |
| Botanix Sb INC | $21.93 | 2025 | Sofdra |
| Janssen Scientific Affairs, LLC | $14.14 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marwa Hakimi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.